Evidence map›Paper›PMID 36669487›Full record

ArticleCell reports. Medicine2023

Humoral signatures of MOG-antibody-associated disease track with age and disease activity.

Marianna Spatola, Omar Chuquisana, Wonyeong Jung, Joseph A Lopez, Eva-Maria Wendel, Sudarshini Ramanathan, Christian W Keller, Tim Hahn, Edgar Meinl, Markus Reindl and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Antibody-Mediated Mechanisms in Autoimmune Neurological Disorders.The European journal of neuroscience · 2026
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Autoimmune encephalitis.Nature reviews. Disease primers · 2025
    Review
  13. Observational
  14. Experimental autoimmune encephalomyelitis pathogenesis alters along animal age: impact of S100B expression.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025
    Article
  15. Article
  16. Ravulizumab and Efgartigimod in Myasthenia Gravis: A Real-World Study.Neurology(R) neuroimmunology & neuroinflammation · 2025
    Article
  17. Anti-IgLON5 Disease 10 Years Later: What We Know and What We Do Not Know.Neurology(R) neuroimmunology & neuroinflammation · 2025
    Review
  18. Observational
  19. Functional Signature of LRP4 Antibodies in Myasthenia Gravis.Neurology(R) neuroimmunology & neuroinflammation · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 11 institutions in 4 countries.

Marianna SpatolaRagon Institute of MGH, MIT and Harvard Medical School, Cambridge, MA 02139, USA. Electronic address: marianna.spatola@gmail.com.
Omar ChuquisanaDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, WWU, Münster 48149, Germany.
Wonyeong JungRagon Institute of MGH, MIT and Harvard Medical School, Cambridge, MA 02139, USA; Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Joseph A LopezBrain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, NSW 2145, Australia; Specialty of Child and Adolescent Health, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia; Brain and Mind Centre, The University of Sydney, Sydney, NSW 2006, Australia.
Eva-Maria WendelDepartment of Pediatric Neurology, Olgahospital/Klinikum Stuttgart, 70174 Stuttgart, Germany.
Sudarshini RamanathanBrain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, NSW 2145, Australia; Brain and Mind Centre, The University of Sydney, Sydney, NSW 2006, Australia; Department of Neurology, Concord Hospital, Sydney, NSW 2139, Australia; Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2006, Australia.
Christian W KellerDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, WWU, Münster 48149, Germany.
Tim HahnInstitute for Translational Psychiatry, University of Münster, 48149 Münster, Germany.
Edgar MeinlInstitute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians-Universität München, 82152 Munich, Germany.
Markus ReindlClinical Department of Neurology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Russell C DaleBrain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, NSW 2145, Australia; Specialty of Child and Adolescent Health, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia; Brain and Mind Centre, The University of Sydney, Sydney, NSW 2006, Australia.
Heinz WiendlDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, WWU, Münster 48149, Germany; Brain and Mind Centre, The University of Sydney, Sydney, NSW 2006, Australia.
Douglas A LauffenburgerMassachusetts Institute of Technology, Cambridge, MA 02139, USA.
Kevin RostásyDepartment of Pediatric Neurology, Children's Hospital Datteln, University Witten/Herdecke, 45711 Datteln, Germany.
Fabienne BrilotBrain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, NSW 2145, Australia; Specialty of Child and Adolescent Health, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia; Brain and Mind Centre, The University of Sydney, Sydney, NSW 2006, Australia.
Galit AlterRagon Institute of MGH, MIT and Harvard Medical School, Cambridge, MA 02139, USA.
Jan D LünemannDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, WWU, Münster 48149, Germany. Electronic address: jan.luenemann@ukmuenster.de.
University Hospital Münster · DEChildren's Hospital at Westmead · AURagon Institute of MGH, MIT and Harvard · USThe University of Sydney · AUHarvard University · USKlinikum Stuttgart · DELudwig-Maximilians-Universität München · DEMassachusetts Institute of Technology · USUniversität Innsbruck · ATUniversity of Münster · DEWitten/Herdecke University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myelin oligodendrocyte glycoprotein (MOG)-antibody (Ab)-associated disease (MOGAD) is an inflammatory demyelinating disease of the CNS. Although MOG is encephalitogenic in different mammalian species, the mechanisms by which human MOG-specific Abs contribute to MOGAD are poorly understood. Here, we use a systems-level approach combined with high-dimensional characterization of Ab-associated immune features to deeply profile humoral immune responses in 123 patients with MOGAD. We show that age is a major determinant for MOG-antibody-related immune signatures. Unsupervised clustering additionally identifies two dominant immunological endophenotypes of MOGAD. The pro-inflammatory endophenotype characterized by increased binding affinities for activating Fcγ receptors (FcγRs), capacity to activate innate immune cells, and decreased frequencies of galactosylated and sialylated immunoglobulin G (IgG) glycovariants is associated with clinically active disease. Our data support the concept that FcγR-mediated effector functions control the pathogenicity of MOG-specific IgG and suggest that FcγR-targeting therapies should be explored for their therapeutic potential in MOGAD.

Indexed as

Immunoglobulin GReceptors, IgGAnimalsHumansMammalsMyelin-Oligodendrocyte GlycoproteinImmunoglobulin GMyelin-Oligodendrocyte GlycoproteinReceptors, IgGantibodydemyelinationFc gamma receptorshumoral signaturesMOGADmyelin oligodendrocyte glycoprotein

Identifiers

PMID36669487
PMCPMC9975090
OpenAlexW4317690310

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.